Insider Selling: Aimmune Therapeutics, Inc. (AIMT) CEO Sells $2,101,285.30 in Stock

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) CEO Stephen George Dilly sold 80,110 shares of Aimmune Therapeutics stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $26.23, for a total value of $2,101,285.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Stephen George Dilly also recently made the following trade(s):

  • On Friday, October 6th, Stephen George Dilly sold 4,047 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $26.31, for a total value of $106,476.57.
  • On Thursday, October 5th, Stephen George Dilly sold 14,689 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $26.24, for a total value of $385,439.36.
  • On Monday, September 25th, Stephen George Dilly sold 100,000 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $25.01, for a total value of $2,501,000.00.
  • On Wednesday, July 26th, Stephen George Dilly sold 50,000 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $21.46, for a total value of $1,073,000.00.

Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) opened at 25.36 on Monday. The company’s market capitalization is $1.28 billion. Aimmune Therapeutics, Inc. has a one year low of $14.87 and a one year high of $27.31. The stock has a 50 day moving average price of $24.34 and a 200-day moving average price of $24.34.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.01). On average, equities research analysts expect that Aimmune Therapeutics, Inc. will post ($2.71) EPS for the current year.

WARNING: This report was posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://transcriptdaily.com/2017/10/09/insider-selling-aimmune-therapeutics-inc-aimt-ceo-sells-2101285-30-in-stock.html.

Several research firms have recently issued reports on AIMT. Wedbush restated an “ourperform” rating and issued a $42.00 price target on shares of Aimmune Therapeutics in a research report on Monday, August 14th. BidaskClub lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. ValuEngine upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 13th. Zacks Investment Research lowered Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Finally, Piper Jaffray Companies set a $38.00 target price on Aimmune Therapeutics and gave the stock a “buy” rating in a report on Thursday, July 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $40.00.

A number of hedge funds and other institutional investors have recently made changes to their positions in AIMT. SG Americas Securities LLC lifted its position in Aimmune Therapeutics by 10.1% in the 2nd quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 499 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Aimmune Therapeutics by 454.1% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,979 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 4,900 shares during the last quarter. Legal & General Group Plc increased its stake in Aimmune Therapeutics by 26.6% in the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 1,634 shares during the last quarter. Voya Investment Management LLC increased its stake in Aimmune Therapeutics by 31.2% in the 2nd quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock valued at $324,000 after buying an additional 3,757 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new stake in Aimmune Therapeutics in the 2nd quarter valued at about $333,000. 72.90% of the stock is currently owned by institutional investors and hedge funds.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply